APVO · XBRL financial data

Aptevo Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (APVO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25†Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Research and development	3,887	3,591*	3,752	3,643	3,103	3,880*	3,633	3,328	4,044	3,535*	3,924	3,696
General and administrative	2,674	2,793*	3,231	2,381	2,110	2,502*	2,847	2,898	3,566	2,461*	2,913	2,747
Operating income (loss)	(6,561)	(6,384)*	(6,983)	(6,024)	(5,213)	(6,382)*	(6,480)	(6,226)	(7,610)	(5,996)*	(6,837)	(6,443)
Other income (expense)	227	188*	149	141	112	70*	72	22	61	190*	140	87
Income tax expense (benefit)	—	—	—	—	—	—	—	—	—	year only	—	—
Net income (loss)	(6,334)	(5,903)*	(6,834)	(5,883)	(5,101)	(6,312)*	(6,408)	(6,204)	(7,549)	(5,806)*	(6,697)	(6,356)
Earnings per share, basic‡ USD per share	(514,403,292.18)	—	(204,732,510.29)	(34,362,139.92)	(9,876,543.21)	—	(73,166.67)	(7,000.00)	(1,858.33)	—	(320.50)	(5.31)
Earnings per share, diluted‡ USD per share	(514,403,292.18)	—	(204,732,510.29)	(34,362,139.92)	(9,876,543.21)	—	(73,166.67)	(7,000.00)	(1,858.33)	—	(320.50)	(5.31)
Weighted average shares, basic‡ thousands of shares	0	—	0	0	0	—	0	1	5	—	21	1,196
Weighted average shares, diluted‡ thousands of shares	0	—	0	0	0	—	0	1	5	—	21	1,196

‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (March 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-33.333333333333336 stock split (December 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-37.03703703703704 stock split (December 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2025); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (June 2025); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-16.666666666666668 stock split (December 2025); filings made before it reported them unadjusted.
† Share count changed about 2x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 244x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 8x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 5x in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 72x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (APVO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25†Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Cash and cash equivalents	19,110	16,904	10,250	8,066	7,753	8,714	2,139	9,410	21,061	21,619	14,525	9,797
Prepaid and other current assets	—	—	—	—	—	1,945	—	—	—	1,462	1,459	1,001
Total current assets	21,126	19,066	12,074	9,579	10,012	10,659	3,607	11,081	22,649	23,081	15,984	10,798
Property and equipment, net	1,011	895	789	697	614	543	482	432	384	303	268	236
Right-of-use asset	4,992	4,881	4,766	4,645	4,520	4,389	4,253	4,111	3,963	3,810	3,650	3,484
Total assets	27,129	24,842	17,629	14,921	15,146	15,591	8,342	15,624	26,996	27,194	19,902	14,519
Accounts payable	—	—	—	—	—	1,242	—	—	—	877	890	1,162
Total current liabilities	6,836	7,224	6,298	5,419	5,882	6,207	5,393	4,891	5,614	6,050	4,760	5,188
Lease liability, non-current	5,575	5,397	5,214	5,025	4,830	4,629	4,422	4,209	3,990	3,763	3,530	3,290
Total liabilities	12,411	12,621	11,526	10,458	10,726	10,836	9,815	9,100	9,604	9,813	8,290	8,478
Accumulated deficit	(217,545)	(223,447)	(230,281)	(236,164)	(241,265)	(247,577)	(253,985)	(260,189)	(269,217)	(275,115)	(281,909)	(288,264)
Total stockholders' equity	14,718	12,221	6,103	4,463	4,420	4,755	(1,473)	6,524	17,392	17,381	11,612	6,041
Total liabilities and equity	27,129	24,842	17,629	14,921	15,146	15,591	8,342	15,624	26,996	27,194	19,902	14,519
Common shares outstanding (cover page)‡ thousands of shares	0	0	0	0	0	0	0	4	20	24	25	1,802

‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (March 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-33.333333333333336 stock split (December 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-37.03703703703704 stock split (December 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2025); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (June 2025); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-16.666666666666668 stock split (December 2025); filings made before it reported them unadjusted.
† Share count changed about 2x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 244x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 8x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 5x in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 72x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (APVO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25†Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Net income (loss)	(6,334)	(5,903)*	(6,834)	(5,883)	(5,101)	(6,312)*	(6,408)	(6,204)	(7,549)	(5,806)*	(6,697)	(6,356)
Stock-based compensation	455*	358*	719	273*	149*	(72)*	180	(163)*	77*	2*	57	58*
Depreciation and amortization	123*	116*	106	91*	84*	71*	61	49*	49*	81*	35	32*
Net cash from operating activities	(6,240)*	(5,253)*	(6,651)	(6,153)*	(5,222)*	(5,759)*	(6,575)	(7,093)*	(6,688)*	(5,236)*	(7,965)	(5,454)*
Net cash from investing activities	—	year only	—	—	—	year only	0	0*	—	year only	0	0*
Proceeds from issuing common stock	1,199*	3,146*	—	—	5,800	year only	0	14,364*	(8,564)*	32,140*	872	726*
Repayments of long-term debt	0*	0*	—	—	—	year only	—	—	—	—	—	—
Net cash from financing activities	4,344*	3,046*	(3)	3,969*	4,909*	6,720*	0	14,364*	18,339*	5,794*	871	726*
Net change in cash	(1,896)*	(2,207)*	(6,654)	(2,184)*	(313)*	961*	(6,575)	7,271*	11,651*	558*	(7,094)	(4,728)*

† Share count changed about 2x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 244x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 8x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 5x in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 72x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aptevo Therapeutics	9,797	not reported	(5,454)*	1.8M	1.8 quarters	Q2 FY26 10-QJun 30, 2026
Traws Pharma	5,016	not reported	(7,504)*	15.4M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Mannatech	6,034	26,650	(792)*	1.9M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
LeonaBio	32,323	not reported	(16,958)*	9.4M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
BioCardia	4,117	not reported	(1,735)*	15.1M	2.4 quarters	Q2 FY26 10-QJun 30, 2026
Alaunos Therapeutics	124	0	(300)*	2.5M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Raphael Pharmaceutical	1	not reported	0*	20.2M	—	Q2 FY26 10-QJun 30, 2026
Scienture Holdings	8,188	344	(3,132)*	41.1M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Bioxytran	177	not reported	(350)*	114.7M	0.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.